Esiashvili Natia, Chiang Kuang-Yueh, Hasselle Michael D, Bryant Cynthia, Riffenburgh Robert H, Paulino Arnold C
Department of Radiation Oncology, Emory University School of Medicine, Atlanta, CA 30322, USA.
Radiother Oncol. 2009 Feb;90(2):242-6. doi: 10.1016/j.radonc.2008.09.017. Epub 2008 Oct 28.
Contribution of total body irradiation (TBI) to renal toxicity in children undergoing the bone marrow transplant (BMT) remains controversial. We report our institutional retrospective study that evaluates the frequency of acute and chronic renal dysfunction in children after using total body irradiation (TBI) conditioning regimens.
Between 1995 and 2003, 60 children with hematological malignancies underwent TBI as part of a conditioning regimen before allogeneic BMT. Patients received 4-14Gy at 1.75-2Gy/fraction in six-eight fractions. Lung shielding was used in all patients to limit lung dose to less than 10Gy; renal shielding was not utilized. All patients had baseline renal function assessment and renal dysfunction post-BM was mainly evaluated on the basis of persistent serum creatinine elevation at acute (0-90 days) and chronic (>90 days) intervals after completion of BMT.
Acute renal dysfunction (ARD) was documented in 27 patients (45%); the majority had concurrent diagnosis of veno-occlusive disease (VOD) or graft-versus-host disease (GVHD) and other potential causes (sepsis, antibiotic). The risk for delayed renal dysfunction (DRD) at 1 year approached 25% for surviving patients. The ARD was strongly linked with the risk of the DRD. There was no statistically significant relationship between ARD, DRD and underlying diagnosis, GVHD, VOD or TBI doses with both univariate and multivariate analyses. The younger age (<5 years) had significantly increased risk for the development of ARD (p=0.011).
Our analysis validates high incidence of renal dysfunction in the pediatric BMT population. In contrast to other reports we did not find total body irradiation dose to be a risk factor for renal dysfunction. Future prospective studies are needed to assess risk factors and interventions for this serious toxicity in children following allogeneic BM.
全身照射(TBI)对接受骨髓移植(BMT)的儿童肾毒性的影响仍存在争议。我们报告了一项机构回顾性研究,该研究评估了采用全身照射(TBI)预处理方案的儿童急性和慢性肾功能不全的发生率。
1995年至2003年期间,60例血液系统恶性肿瘤患儿在接受异基因BMT前接受了TBI作为预处理方案的一部分。患者接受4-14Gy照射,分六至八次给予,每次1.75-2Gy。所有患者均采用肺部屏蔽以将肺部剂量限制在10Gy以下;未采用肾脏屏蔽。所有患者均进行了基线肾功能评估,BMT后肾功能不全主要根据BMT完成后急性(0-90天)和慢性(>90天)期间血清肌酐持续升高来评估。
27例患者(45%)出现急性肾功能不全(ARD);大多数患者同时诊断为静脉闭塞性疾病(VOD)或移植物抗宿主病(GVHD)以及其他潜在病因(败血症、抗生素)。存活患者1年时发生延迟性肾功能不全(DRD) 的风险接近25%。ARD与DRD的风险密切相关。单因素和多因素分析显示,ARD、DRD与潜在诊断、GVHD、VOD或TBI剂量之间均无统计学显著关系。年龄较小(<5岁)的患者发生ARD的风险显著增加(p=0.011)。
我们的分析证实了儿科BMT人群中肾功能不全的高发生率。与其他报告不同,我们未发现全身照射剂量是肾功能不全的危险因素。未来需要进行前瞻性研究,以评估异基因BM后儿童发生这种严重毒性反应的危险因素和干预措施。